1) Donnez J, et al : Ovarian tissue cryopreservation and transplantation : a review. Hum Reprod Update 12 : 519─535, 2006
2) Levine J, et al : Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 28 : 4831─4841, 2010
3) Anderson RA, et al : The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21 : 2583─2592, 2006
4) Bines J, et al : Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14 : 1718─1729, 1996
5) Loren AW, et al : Fertility preservation for patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31 : 2500─2510, 2013
6) Behringer K, et al : Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy : a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 23 : 7555─7564, 2005
7) Blumenfeld Z, et al : Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 89 : 166─173, 2008
8) Grigg A : The impact of conventional and high-dose therapy for lymphoma on fertility. Clin Lymphoma 5 : 84─88, 2004
9) Meirow D : Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 33 : 65─76, 1999
10) Bar-Joseph H, et al : Doxorubicin-induced apoptosis in germinal vesicle(GV)oocytes. Reprod Toxicol 30 : 566─572, 2010
11) Ben-Aharon I, et al : What lies behind chemotherapy-induced ovarian toxicity? Reproduction 144 : 153─163, 2012
12) 筒井建紀 : 化学療法による卵巣毒性.がん・生殖医療─妊孕性温存の診療(鈴木 直,竹原 祐 編).pp42─51,医歯薬出版,2013
13) von Wolff M, et al : Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy--a technique in its infancy but already successful in fertility preservation. Eur J Cancer 45 : 1547─1553, 2009
14) Imai A, et al : Preservation of female fertility during cancer treatment. Reprod Med Biol 7 : 17─27, 2008
15) Imai A, et al : Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 63 : 102─106, 2007
16) Badawy A, et al : Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage : prospective randomized study. Fertil Steril 91 : 694─697, 2009
17) Beck-Fruchter R, et al : GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy : a review of the clinical data. Hum Reprod Update 14 : 553─561, 2008
18) Blumenfeld Z : ZORO study : discrepancy between the conclusion and the results. J Clin Oncol 29 : 3340 ; author reply 3341─3342, 2011
19) Del Mastro L, et al : Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer : a randomized trial. JAMA 306 : 269─276, 2011
20) Gerber B, et al : Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy : the GBG 37 ZORO study. J Clin Oncol 29 : 2334─2341, 2011
21) Meirow D, et al : The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 19 : 1294─1299, 2004
22) 古井辰郎,他 : 卵巣保護(GnRHアゴニスト).がん・生殖医療─妊孕性温存の診療(鈴木 直,竹原 祐 編).pp182─187,医歯薬出版,2013
23) 日本乳癌学会 : 乳癌診療ガイドライン.金原出版,2011